Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03315910 · ClinicalTrials.gov registry record · Phase 4

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

A Phase 4 study of Smoking Cessation, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 4
Development phase
807
Enrollment target
18
Study locations

NCT03315910: Active Phase 4 study of Smoking Cessation, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03315910 is a Phase 4 study of Smoking Cessation that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 807 participants, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (72% higher). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03315910, a Phase 4 study of Smoking Cessation, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
807 participants
Enrollment target
18
Study locations

Study Summary

This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the benefits of lung cancer screening by providing a blue print of best practices for screening sites to deliver tobacco treatment to their patients who are smokers, in a way that does not add burden to screening site staff and increases the chances of patients quitting smoking.

Primary Outcome

biochemical verification of smoking abstinence will be conducted Consistent with Intent to Treat, unless self reported smoking abstinence is biochemically verified, (\<3 ng/ml for mailed salivary cotinine assay) for participants who fail to return the saliva sample, the cessation outcome will be considered non-abstinent.

Conditions Studied

Smoking Cessation

Interventions

  • BEHAVIORAL Motivational Interviewing (MI)
  • DRUG Nicotine Replacement Therapy (NRT)
  • DRUG Nicotine Lozenge
  • BEHAVIORAL Message Framing
  • OTHER saliva sample

Study Locations (18)

New York

  • NYU Winthrop Hospital - Mineola
  • Memorial Sloan Kettering Cancer Center - New York
  • Weill Cornell Medical Center - New York
  • Montefiore Medical Center (Data Collection Only) - The Bronx

California

  • University of Southern California (Data Collection Only) - Los Angeles
  • John Muir Health - Walnut Creek

Illinois

  • Rush University Medical Center - Chicago
  • Riverside Healthcare - Kankakee

Michigan

  • Henry Ford Hospital (Data collection only) - Detroit
  • Munson Healthcare - Traverse City

Georgia

  • WellStar Health System - La Grange

Indiana

  • St. Mary Medical Center, Community Healthcare System - Crown Point

Iowa

  • MercyOne Des Moines Medical Center (Data Collection Only) - Des Moines

Maine

  • Maine Medical Center Cancer Institute - Scarborough

Trial Details

FieldValue
Enrollment Target 807 participants
Start Date 2017-10-10
Est. Completion 2026-10
Phase Phase 4
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT03315910 still lists

NCT03315910 is an interventional study that assigns participants to a tested intervention. The registered 807 participants enrollment target is mid-sized for trials with a published cap, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (72% higher).

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 5 interventions - of which Motivational Interviewing (MI) is the first listed.

NCT03315910 lists 18 locations in 12 states (New York, California, Illinois).

Frequently Asked Questions

What is clinical trial NCT03315910 about?

NCT03315910 is a clinical study titled "Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites". This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the benefits of lung cancer s...

What is the current status of trial NCT03315910?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 807 participants. The study started on 2017-10-10. Estimated completion is 2026-10.

What conditions does trial NCT03315910 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT03315910?

The interventions under investigation include: Motivational Interviewing (MI) (BEHAVIORAL), Nicotine Replacement Therapy (NRT) (DRUG), Nicotine Lozenge (DRUG), Message Framing (BEHAVIORAL), saliva sample (OTHER).

Who is sponsoring clinical trial NCT03315910?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03315910 being conducted?

This trial has 18 study locations across California, Georgia, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03315910's enrollment target sits among peer trials

807 30th of 188 higher than 159 of 188 other Smoking Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06529094 · 808 participants · NA

    Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06065098 · 806 participants · NA

    Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

  • NCT05519085 · 810 participants · Phase 3

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03315910, the US trial registry maintained by the National Library of Medicine. NCT03315910 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.